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Abstract
Background: The presence of lymph node metastases remains the most reliable prognostic predictor and the
gold indicator for adjuvant treatment in colon cancer (CC). In spite of a potentially curative resection, 20 to 30% of
CC patients testing negative for lymph node metastases (i.e. pN0) will subsequently develop locoregional and/or
systemic metastases within 5 years. The presence of occult nodal isolated tumor cells (ITCs) and/or
micrometastases (MMs) at the time of resection predisposes CC patients to high risk for disease recurrence. These
pN0micro+ patients harbouring occult micrometastases may benefit from adjuvant treatment. The purpose of the
present study is to delineate the subset of pN0 patients with micrometastases (pN0micro+) and evaluate the
benefits from adjuvant chemotherapy in pN0micro+ CC patients.
Methods/design: EnRoute+ is an open label, multicenter, randomized controlled clinical trial. All CC patients (age
above 18 years) without synchronous locoregional lymph node and/or systemic metastases (clinical stage I-II
disease) and operated upon with curative intent are eligible for inclusion. All resected specimens of patients are
subject to an ex vivo sentinel lymph node mapping procedure (SLNM) following curative resection. The
investigation for micrometastases in pN0 patients is done by extended serial sectioning and immunohistochemistry
for pan-cytokeratin in sentinel lymph nodes which are tumour negative upon standard pathological examination.
Patients with ITC/MM-positive sentinel lymph nodes (pN0micro+) are randomized for adjuvant chemotherapy
following the CAPOX treatment scheme or observation. The primary endpoint is 3-year disease free survival (DFS).
Discussion: The EnRoute+ study is designed to improve prognosis in high-risk stage I/II pN0 micro+ CC patients by
reducing disease recurrence by adjuvant chemotherapy.
Trial Registration: ClinicalTrials.gov: NCT01097265
Background
Colorectal cancer is the second most commonly diag-
nosed malignancy in men and women in the Nether-
lands with increasing incidence due to growth and
ageing of the general population [1]. The presence of
lymph node metastases remains the most reliable prog-
nostic predictor and the gold indicator for adjuvant
treatment in colon cancer (CC) [2]. Interestingly, in a
large percentage of patients without lymph node
metastases in the surgical specimen, who are therefore
not subjected to adjuvant chemotherapy, represent with
disease recurrence. In about 10% of the patients with
stage I (Dukes A) and 15-30% with stage II (Dukes B)
disease recurrent locoregional or distant metastases
develop within 5 years [2-4]. One possible factor could
be the presence of occult lymph node metastases at the
time of presentation and surgical resection. Evidence
has emerged showing a significant amount of nodal
metastases being smaller than 2 mm or less (<0.2 mm
isolated tumor cells [ITC]; 0.2 - 2 mm micrometastasis
[MM]) and, therefore, likely to be missed during con-
ventional gross pathological specimen examination. }
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any medium, provided the original work is properly cited.[3-5] Focused examination methods, such as more
extensive nodal examination by serial sectioning or step
sectioning, or molecular detection of metastatic nodal
cells by immunohistochemistry (IHC) or reverse tran-
scriptase-polymerase chain reaction (RT-PCR), increase
the likelihood of finding these tumour deposits. How-
ever, these focused examination methods are expensive
and time consuming, and therefore not applicable to all
lymph nodes derived from the surgical specimen. By
using sentinel lymph node mapping (SLNM) the nodes
at highest risk of harbouring tumour deposits can be
potentially detected and more thoroughly examined.
The ex vivo SLNM procedure is technically easy, as the
procedure is executed extracorporally by injection peri-
tumoral blue dye subserosally or submucosally after
which gentle massage of the injection site is performed
[5-11]. Blue coloured lymph nodes are excised or
marked by sutures. The ex vivo SLNM procedure is
characterized by a high accuracy of 90-100%, and nega-
tive predictive value of 80-100%[6-11]. A rate of 19-57%
upstaging is observed [6-11].
Current knowledge about the prognostic relevance of
nodal micrometastases and isolated tumor cells has ade-
quately been reviewed in 2004 separately by Iddings and
Nicastri [3,4]. They concluded that a suggestion of prog-
nostic relevance could be made for micrometastatic dis-
ease related to worsened disease-free survival (DFS) and
overall survival (OS). The meta-analysis performed by
Iddings showed a decreased 3-year DFS and OS of
respectively 78% and 78% in pN0micro+ patients com-
pared to 90% and 97% in pN0micro- patients [4]. New
evidence from two large international prospective obser-
vational studies shows a clear negative prognostic effect
of micrometastatic nodal disease [5]. The 4-year DFS
detoriated from 94% to 78% with the presence of nodal
micrometastasis [5]. A solid conclusion, however, could
not be made because of the lack of well-designed, well
powered, controlled clinical trials. Data from other solid
organ malignancies like breast cancer links micrometa-
static disease to a worsened prognosis [12]. Several pro-
spective trials are currently recruiting (see table 1).
However, an randomized, controlled clinical trial of sig-
nificant magnitude is needed to answer this clinically
relevant question.
Nowadays, adjuvant chemotherapy is only offered to
high risk stage I-II colon cancer patients in the Nether-
lands [2]. Stage I-II CC patients without risk factors are
thought not to benefit from adjuvant treatment. Indivi-
dual randomized trials did not show a significant survi-
val benefit in stage II colon cancer patients [2]. The
results of meta-analyses and systematic reviews show at
the most a slight disease-free survival benefit of adjuvant
chemotherapy in stage II disease [2]. However, to stress
out the importance of further investigation, stage I-II
CC patients do suffer from disease recurrence and their
overall 5-year survival is just around 70-80%. Even stage
II CC patients without risk factors have been shown in
several studies to benefitf r o ma d j u v a n tt r e a t m e n t
[13,14]. It is because of these results that in Eastern
countries and the United States stage II CC patients
with or without micrometastatic disease do receive adju-
vant treatment. Thus, there is an international need for
better delineation of high-risk stage I-II CC patients
who probably should be offered adjuvant treatment.
Methods/Design
Study objectives
To determine the benefits from adjuvant chemotherapy
in pN0micro+ CC patients on 3-year disease-free survival
compared to non-treated pN0micro+ CC patients.
Primary endpoint
Primary endpoint is 3-year DFS in study groups (pro-
portion of patients without local or distant recurrence,
or second primary of same of other cancer, death from
same cancer of any other cause during the defined per-
iod of time).
Secondary endpoints
Secondary endpoints are rate of upstaging in pN0 colo-
nic cancer patients (total number pN0micro+ patients ×
100/total number pN0 colon cancer patients) and 3-year
overall survival.
Design
EnRoute+ is an open label, multicenter, randomized
controlled clinical trial. A centrally-performed, compu-
ter-generated randomization procedure is instituted. Eli-
gible patients are randomly assigned at a 1:1 ratio to
receive treatment respectively without or with che-
motherapy using block-randomisation per participating
center. Design, flow chart and follow up are presented
in Figures 1, 2 and 3.
Study groups are defined according the randomisation
group and pathological examination result.
group A pN0micro+ with chemotherapy
group B pN0micro+ without chemotherapy
group C pN0micro- without chemotherapy
Table 1 Currently recruiting studies
University Hospital, Strasbourg, France
(C. Brigand)
2007 - 2014 N = 140
Jonsson Comprehensive Cancer Center
(A. Bilchik)
2009 - 2011 N = 300
John Wayne Cancer Institute (S. Baker) 2000 - 2011 N = 200
University Hospital, Basel, Switzerland
(C. Viehl)
2004 - 2007 N = 225
Source: http://www.clinicaltrials.gov
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Subjects will be enrolled in multiple academic and non-
academic (teaching and non-teaching) hospitals in the
Netherlands.
Patients
A total of 1000 adult patients of both sexes with pN0mi-
cro+ will be randomized to receive adjuvant
chemotherapy.
Eligibility criteria
Inclusion criteria for randomization
-p N 0 micro+ colon cancer patients (stage I/II, Dukes
A/B)
- patients deemed to be fit for chemotherapy treat-
ment (WHO classification ≤ 1; ASA classification ≤
2)
Exclusion criteria for randomization
- rectal cancer
- previous chemotherapy
- high risk pN0 patient according to:
○ less then 10 lymph nodes detected in resected
specimen, or
○ invasion in other organs (T4NxMx), or
○ colon perforation at presentation, or
○ clinically relevant obstruction at presentation,
or
○ angioinvasion at conventional pathological
examination
- positive nodal involvement or advanced disease
(stage III/Dukes C/Dukes D)
- haematological impairments (anemia, leucopenia,
thrombocytopenia within 7 days before start of che-
motherapy treatment)
○ renal function impairments (creat.clearance ≤
60 ml/min within 7 days before start of che-
motherapy treatment)
- liver enzyme serum alterations within 7 days before
start of treatment
To be assessed for 
eligibility (n = 3500)
To be randomised
(n = 1000)
Incidence colon 
cancer (n = 7000)
Not meeting randomisation
criteria ( n = 2400)
Refusal to participate (n = 75)
Other reasons (n = 25)
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be lost to follow up (n = 13) To be lost to follow up (n = 13)
To be analysed (n = 487) To be analysed (n = 487)
To be assessed for 
eligibility (n = 3500)
To be assessed for 
eligibility (n = 3500)
To be randomised
(n = 1000)
To be randomised
(n = 1000)
Incidence colon 
cancer (n = 7000)
Incidence colon 
cancer (n = 7000)
Not meeting randomisation
criteria ( n = 2400)
Refusal to participate (n = 75)
Other reasons (n = 25)
Not meeting randomisation
criteria ( n = 2400)
Refusal to participate (n = 75)
Other reasons (n = 25)
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be allocated to intervention (n = 500)
- Receive allocated intervention
- not receive allocated intervention
To be lost to follow up (n = 13) To be lost to follow up (n = 13) To be lost to follow up (n = 13) To be lost to follow up (n = 13)
To be analysed (n = 487) To be analysed (n = 487) To be analysed (n = 487) To be analysed (n = 487)
Figure 1 EnRoute+ study according to CONSORT
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Page 3 of 9- other current serious illness or medical conditions
○ severe cardiac illness (NYHA class III-IV, see
Appendix)
○ significant neurologic or psychiatric disorders
○ uncontrolled infections
○ active disseminated intravascular coagulation
○ other serious underlying medical conditions
that could impair the ability of the patient to
participate in the study
- definite contraindications for the use of
corticosteroids
- use of immunosuppressive or antiviral drugs
Figure 2 EnRoute+ flow chart
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Page 4 of 9- any other experimental drugs within a 4-week per-
i o dp r i o rt os t a r to fs u r g e r ya n da d j u v a n tc h e -
motherapy and/or throughout/during the study
period
- pregnancy or lactation
- patients unable to comply with requirements of the
study
Ethics, informed consent
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and ‘good clinical
practice’ guidelines. The independent central ethics
committee approved the final protocol on 26
th July
2010. Oral and written informed consent is obtained
from the patient before inclusion in the trial.
Safety
No additional risks for patients are introduced by the ex
vivo SLNM procedure as the complete procedure is per-
formed extracorporally. Participation in the randomiza-
tion study brings risks and discomfort for the patient
common to adjuvant systemic chemotherapeutic treat-
ment as given to patients with stage III colon cancer
(CAPOX scheme). Dose limiting toxicities of oxaliplatin/
capecitabine include diarrhoea, abdominal pain, nausea,
stomatitis and hand-foot syndrome (hand-foot skin reac-
tion, palmar-plantar erythrodysesthesia). Most adverse
reactions are reversible and do not require permanent
discontinuation of therapy, although doses may need to
be withheld or reduced. A potential negative effect on
prognosis can be expected in patients not receiving
adjuvant chemotherapy.
Statistical analysis
Intention-to-treat
The analysis will be performed on the basis of an inten-
tion-to-treat (ITT) population and with respect to ITT
principles. Also a per-protocol (chemotherapy versus no
adjuvant treatment) analysis will be performed.
Interim analysis
An interim analysis will be performed when half of the
required number of events have been observed. Based
on the O’Brien-Fleming alpha-spending function, the
first analysis will be performed at nominal alpha level
0.003, the second at nominal alpha level 0.047, to ensure
an overall alpha of 0.05.
Sample size
The sample size is calculate to be (N=) 973 patients
(control group [B] 486 pts/145 events, treatment group
[C] 487 pts/102 events with 90% power and a signifi-
cance level of 0.05. Loss to follow up is expected to be
26 patients. Median follow up for primary outcome is 3
years. Accrual rate is expected to be at least 300
patients/year, which results in a maximum total accrual
time of 4 years. Median follow up of 3 years is reached
after 5 years total study time.
Treatment program
Eligible patients are selected and informed by local clini-
cians. Written consent is obtained and the patient is pre-
pared for surgery according to the ERAS protocol. The
method of surgery (i.e. laparoscopic or open) is chosen
by the surgeon together with the patient. The datacenter
is informed by the treating clinician about registration of
the patient into the trial and the preoperative CRF is
send to the datacenter. The operation is performed by a
certified surgeon, or supervised surgical resident. Surgery
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Figure 3 EnRoute+ follow up. OCV: outpatient clinic visit. CEA: carcinoma embryonic antigen abd. US: abdominal ultrasonography.
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Page 5 of 9is performed according to anatomical and oncological
principles dictated by the location of the tumour. The
adjacent mesocolon is dissected including its base and
excised en-block. Within fifteen minutes of the resection
the ex vivo SLNM is performed. The specimen is opened
at the anti-mesenteric side. When the tumour is identi-
fied, 1 ml of Patent Blue V dye is injected into the sub-
mucosa circumferentially to the tumour, using a
tuberculin syringe. The injection sites are then gently
massaged for up to five minutes to push the tracer into
the lymphatic vessels. Blue coloured sentinel nodes are
identified and marked with a suture. The specimen is
transferred fresh to the pathology laboratory, when possi-
ble according to local pathological facilities, for further
examination and processing. The specimen is put in for-
malin within 15 minutes after the SLNM procedure,
when local pathological facilities dictate formalin
embedded transportation of the specimen. If fresh
received, a sample is taken from the primary tumor for
tumor banking and side-study purposes. The pathologist
examines the specimen using conventional methods and
identifies the blue stained nodes and puts them into
marked cassettes so that they can be examined by micro-
scopic examination. Sentinel and non-sentinel lymph
nodes are bivalved. Each section is analyzed using con-
ventional histologic staining with hematoxylin and eosin
(H&E). Efforts are made to analyze at least 10 lymph
nodes per specimen. Detection of lymph node metastases
is performed by microscopic examination in sentinel and
non-sentinel nodes. The patient is excluded for focussed
examination, when macroscopic metastases are present
(pN+) or angioinvasion is detected (see exclusion cri-
teria). In pN0 patients sentinel lymph nodes are addition-
ally sliced at four levels at 150 μm intervals. All sections
are stained with Pan-Cytokeratin (LU-5). Positive cyto-
keratin lymph node metastases are defined as ITC <0.2
mm or MM 0.2 - 2 mm (see Table 2). Rare single cells
staining positive with IHC that lack cytologic characteris-
tics of malignancy are considered tumor-negative.
Tumours are staged according to the AJCC TNM classi-
fication 2002 (Sixth Edition). Adjuvant chemotherapy is
provided according to the CAPOX (XELOX) protocol
(capecitabine (Xeloda
®) and oxaliplatin(Eloxatin
®)).
Monitoring
Research nurses monitor the participating centres and
patients. Every 6 months a random selection of partici-
pating centres is visited by research nurses checking, at
least, 10% of patient’s data.
Follow-up
Patients are followed during their hospital stay. Patients
are kept in follow up for five years according to national
guidelines (see Figure 3) [2].
Discussion
Recurrent locoregional and/or systemic disease in stage
I/II colon cancer is a significant clinical and social
health care problem. The fact of high disease recurrence
in stage I-II colon cancer patients is the basis of the
study idea and the justification for the study. Around
7000 new colon cancer patients are diagnosed yearly in
the Netherlands at this moment and the incidence will
rise in the coming decades [2]. Of these new colon can-
cer patients respectively 16 and 38% have stage I or
stage II disease [15]. Therefore, yearly approximately
3500 new stage I-II patients are at risk for disease recur-
rence. A upstaging rate of 30% is expected to be
observed by using SLNM, serial sectioning and IHC for
micrometastatic disease detection [6-11]. Approximately
1050 are at high risk for disease recurrence. Nowadays,
adjuvant chemotherapy is only offered to high risk stage
II colon cancer patients in the Netherlands [2]. Stage II
CC patients without risk factors are thought not to ben-
efit from adjuvant treatment. Individual randomized
trials did not show a significant overall survival benefit
in stage II colon cancer patients [2]. The results of
meta-analyses and systematic reviews show at the most
a slight disease-free survival benefit of adjuvant che-
motherapy in stage II disease of 3-6% absolute risk
reduction in disease-free survival (3.8 - 6% ARR in 5-yr
DFS by Figueredo et al, 3% ARR in 5-yr DFS in the
IMPACT-B2 study, 4% ARR in 5-yr DFS in the Gill-
study [2,16-18].
According to SEER data 5-year overall survival data of
stage IIa (T3N0M0), IIb (T4N0M0) and IIIa (T1-
2N1M0) and b (T3-4N1M0) are respectively 84.7%,
Table 2 Definitions of isolated tumor cells (ITCs) and micrometastases (MMS)
Definitions used in EnRoute⊕ Study
Isolated Tumor Cells (ITCs) Micrometastases (MMs)
Size < 0.2 mm 0.2 - 2 mm
Localization No defining criterion No defining criterion
Detection method HES and/or IHC HES and/or IHC
Formal designation (present vs absent) pN0i+ vs pN0i- pN0mi+ vs pN0mi-
Designation for study purposes if present pN0micro+ pN0micro+
HES hematoxylin and eosin stain; IHC immunohistochemistry.
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Page 6 of 972.2%, 83.4% and 64.1% [19]. The MOSAIC-trial
observed a 4-year DFS of untreated versus treated colon
cancer stage II and III of respectively 85-87.6% and
66.5-74.1% [20]. The XELOXA-trial found a 3-year DFS
of 66.5-70.9% (untreated versus treated) in stage III
colon cancer [21]. An 9% absolute risk reduction on 5-
year OS (85.4% in the surgery-only group and 94.2%
adjuvant chemotherapy group) was observed in
T3N0M0 patients following adjuvant chemotherapy in a
large retrospective study [13]. A similar result was
observed in 468 stage II patients (i.e. 8% 4-year OS risk
reduction of 70% to 78%) [22]. In an Australian popula-
tion-based cohort-study patients with good prognosis
(T3, no lymphovascular invasion) showed improved 5-
year survival rate with chemotherapy from 85 to 95% (P
= 0.064, log-rank test) in women but showed no change
in men (84 vs 82%). The poor prognosis (T4 and/or pre-
sence of lymphovascular invasion) patients, survival rates
for both women (65 vs 79%) and men (72 vs 78%)
improved with the use of chemotherapy, however, did
not reach significance in either group (P = 0.22 and P =
0.26, respectively) [14]. It is therefore assumed that the
use of adjuvant chemotherapy in high-risk pN0 colon
cancer patients could result in clinical significant health
benefits for individual patients.
The detection of sentinel nodes using a SLNM proce-
dure has been extensively investigated [5-9,11,23-29].
For correct interpretation of these data a gross distinc-
t i o nh a st ob em a d eb e t w e e ni )in vivo and ex vivo pro-
cedures; ii) immunohistochemical (IHC) or reverse-
transcriptase polymerase chain reaction (RT-PCR) occult
nodal metastatic disease detection.
The in vivo SLNM procedure is characterized by a
more difficult technical procedure, most notably during a
laparoscopic colonic resection, as a subserosal dye injec-
tion is performed preoperatively [23-29]. The accuracy
and negative predictive value of in vivo SLNM proce-
dures are high and range from 90 to 95% and 93 to 97%
respectively [23-29]. Upstaging was observed in 28-35%
of H&E pN0 patients [23-29]. The ex vivo SLNM proce-
dure is technically much easier, as the procedure is exe-
cuted extracorporally by injection peritumoral blue dye
subserosally or submucosally after which gentle massage
of the injection site is performed [6-11]. The ex vivo
SLNM procedure is characterized also by a high accuracy
of 90-100%, and negative predictive value of 80-100%
[6-11]. A rate of 19-57% upstaging is observed [6-11].
Although most studies combine data of colon and rec-
tal cancer, a clear distinction in sentinel lymph node
mapping between both cancers has been observed in
some well-designed studies [6,11,26]. The accuracy of
negative predictive value of SLNM in rectal cancer is
estimated to be as low as 76% and 65% respectively, and
rectal cancers are therefore excluded from inclusion [6].
T h em e t h o do fe x a m i n a t i o n ,i . e .I H Co rR T - P C R ,i s
also an important determinant of outcome [3,4]. Cyto-
keratin is a cellular marker for epithelial origin, adhering
to constituents of the cytoskeleton of both normal and
malignant cells. However, epithelial cells are not normal
constituents of lymphoid tissue, and morphological
examination of all cytokeratin-positive cells for second-
ary malignant characteristics is mandatory. Most studies
used an IHC methodology, with little similarity in
immunohistochemical markers unfortunately
[3,4,6-9,24,30]. A high variety in the use of molecular
markers for RT-PCR inhibits the selection of the one
with highest accuracy and negative predictive value
[3,4,23]. The best correlation between micrometastatic
disease and worsened DFS and OS has been observed in
RT-PCR detected occult disease in comparison to IHC
[3,4]. The strength of the evidence of this observed cor-
relation is weak though. Furthermore, RNA is subtracted
from halve of a sentinel node in RT-PCR procedures.
This unables pathologists the examination of secondary
malignant characteristics with H&E colouring. More-
over, the authors of the most recent prospective clinical
trial using RT-PCR stated that quantified RT-PCR assays
may be of value when cytokeratin immunohistochemis-
try fails to detect sentinel lymph node metastasis [23].
Therefore, no definitive preference for IHC or RT-PCR
methods can be given. For practical arguments, includ-
ing the possibility for all Dutch hospitals to participate
in the study, a controlled clinical trial using an ex vivo
SLNM procedure with focussed nodal examination by
cytokeratin IHC techniques is proposed.
Adjuvant chemotherapy is provided according to the
CAPOX (XELOX) protocol (capecitabine (Xeloda
®)a n d
oxaliplatin(Eloxatin
®)). This CAPOX (XELOX) protocol
is assumed to be comparable in therapeutical effect and
toxicity to the currently used FOLFOX-4 protocol, and
more patient friendly because of the oral supplementa-
tion of chemotherapy (capecitabine) [2].
As primary endpoint is 3-year DFS chosen as surro-
gate endpoint for overall survival. Colon cancer recur-
rence is most notably observed in the first years after
initial treatment [2,31]. Furthermore, 3-year DFS is
recognized as an appropriate surrogate end point for
overall 5-year survival in colon cancer trials [32-34].
Conclusion
Around 30% of all pN0 colon cancer patients will
develop locoregional and/or distant disease recurrence.
Adjuvant systemic chemotherapy is thought to decrease
disease recurrence in high risk pN0micro+ patients. A
large patient group is subject to this high disease recur-
rence rate. Therefore, it is justified to perform the pro-
posed trial in a multicenter design in the Netherlands to
answer the clinical relevant question of the role of
Lips et al. BMC Surgery 2011, 11:11
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Page 7 of 9micrometastatic disease on prognosis in stage I-II colon
cancer patients.
Abbreviations
CC: colon cancer; ITC: isolated tumor cell; MM: micrometastasis; SLNM:
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